Clinical Outcomes of Severe Lassa Fever in West Africa: A Systematic Review and Meta-Analysis
Authors:
- Azuka Patrick OkwuraiweAOAzuka Patrick Okwuraiwe
- Chizaram Anselm OnyeaghalaCOChizaram Anselm Onyeaghala
- Obiageli Theresa OzoudeOOObiageli Theresa Ozoude
- Muritala Odidi SuleimanMSMuritala Odidi Suleiman
- Samirah Nndwan Abdu-AguyeSASamirah Nndwan Abdu-Aguye
- Nkolika Jacinta EzekweluNENkolika Jacinta Ezekwelu
- Tolulope Amos OyeniyiTOTolulope Amos Oyeniyi
- Ayodapo Oluwadare JegedeAyodapo Oluwadare Jegede
- Adaeze Elfrida EgwudoAEAdaeze Elfrida Egwudo
- Oluchukwu Perpetual OkekeOOOluchukwu Perpetual Okeke
- Olunike Rebecca AbodunrinOAOlunike Rebecca Abodunrin
- Folahanmi Tomiwa AkinsoluFAFolahanmi Tomiwa Akinsolu
Open Access
- 30 September 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (10) , 1504
Abstract
Lassa fever (LF) is an acute viral hemorrhagic fever that poses a substantial public health security threat in West Africa. The non-specific clinical presentation of LF, coupled with a lack of reliable point-of-care diagnostics, means delayed diagnosis, leading to severe complications and mortality during epidemics. A systematic review and meta-analyses were performed by conducting an extensive online search using PubMed, Web of Science, Scopus, CINAHL, and Google Scholar (PROSPERO protocol identifier number CRD42024587426). Only peer-reviewed studies written in English were included in publications from 1 September 2014, to 31 August 2024. The analysis and reporting followed PRISMA guidelines. The quality of the included studies was assessed using the critical appraisal tools developed from the Joanna Briggs Institute Systematic Review Checklist for cohort studies. We included 19 studies that contained data from 4177 patients hospitalized with LF of any age. Most included studies employed a retrospective cohort design and were conducted in Nigeria (16/19; 84.2%). The mortality rate was highest in a Sierra Leonean study (63.0%), whereas a group-based analysis of Nigerian studies using a random-effects model identified Owo as having the highest mortality rate of 13% (95% CI: 6–23; I2 = 98%). The pooled mortality rate for severe LF was 19% (95% confidence interval [CI]:10–32). The most common complications of LF are acute kidney injury (AKI) at a pooled proportion of 19% (95% CI; 13–26; I2 = 89%)), followed by abnormal bleeding at a pooled proportion of 17% (95% CI; 9–30; I2 = 98%), and central nervous system (CNS) dysfunction at a pooled proportion of 15% (95% CI; 6–32; I2 = 98%). With one out of every five hospitalized LF patients likely to die in West Africa, accelerating the development of rapid diagnostic tests, licensed vaccines, and novel therapeutics is crucial. Strengthening community engagement and risk communication, developing regional treatment guidelines, decentralizing LF care units, and training healthcare workers using a harmonized curriculum will enhance early diagnosis and effective case management, thereby reducing severe complications and mortality.Keywords
Funding Information
- Nigerian Institute for Medical Research Foundation (NF-GMTP-24-152809)
This publication has 34 references indexed in Scilit:
- Lassa fever outbreaks, mathematical models, and disease parameters: a systematic review and meta-analysisThe Lancet Global Health, 2024
- Lassa fever research priorities: towards effective medical countermeasures by the end of the decadeThe Lancet Infectious Diseases, 2024
- A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virusProceedings of the National Academy of Sciences, 2023
- Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort studyThe Lancet Global Health, 2021
- Acute kidney injury and mortality in pediatric Lassa fever versus question of access to dialysisInternational Journal of Infectious Diseases, 2021
- Prevalence and outcome of Lassa fever among hospitalized patients in Ebonyi State, Nigeria, 2018–2019Virus Research, 2020
- Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort studyThe Lancet Infectious Diseases, 2018
- Detecting small‐study effects and funnel plot asymmetry in meta‐analysis of survival data: A comparison of new and existing testsResearch Synthesis Methods, 2017
- New Hosts of The Lassa VirusScientific Reports, 2016
- Central nervous system manifestations of lassa fever in Nigeria and the effect on mortalityJournal of the Neurological Sciences, 2013